脂肪细胞因子在心血管疾病中的研究进展
Research Progress of Adipocytokines in Cardiovascular Diseases
DOI: 10.12677/ACM.2022.12101343, PDF,   
作者: 樊纯祯：青岛大学附属青岛市市立医院，山东 青岛；王军珂：青岛大学青岛医学院，山东 青岛；戴红艳*：青岛市市立医院心脏中心，山东 青岛
关键词: 心血管疾病；脂肪细胞因子；脂联素；瘦素；白脂素；Cardiovascular Disease； Adipocytokines； Adiponectin； Leptin； Asprosin
摘要: 心血管疾病(Cardiovascular disease, CVD)在我国患病率和致死率一直高居榜首，至今仍处于上升阶段，影响个人健康的同时也加重了社会负担。而肥胖是心血管病的独立危险因素。脂肪组织不仅可以储存脂肪，也是重要的内分泌器官，能分泌大量的脂肪因子，对调控代谢、抗炎症反应、抗氧化应激等方面有重要作用。随着脂肪细胞因子与代谢综合征、卒中等关系的深入研究，人们对其与心血管疾病的关系也愈发关注。本文总结了几种脂肪细胞因子在心血管疾病中的研究进展，包括脂联素(Adiponectin)、瘦素(leptin)、白脂素(Asprosin)。
Abstract: Cardiovascular disease (CVD) has the highest morbidity and mortality in my country, and it is still on the rise. It affects individual health and also increases social burden. Obesity is an independent risk factor for cardiovascular disease. Adipose tissue can not only store fat, but also an important endocrine organ, which can secrete a large number of adipokines, which play an important role in regulating metabolism, anti-inflammatory response, and anti-oxidative stress. With the in-depth study of the relationship between adipocytokines and metabolic syndrome, stroke, etc., people are paying more and more attention to the relationship between adipocytokines and cardiovascular diseases. This paper summarizes the research progress of several adipocytokines in cardiovascular diseases, including Adiponectin, leptin, Asprosin.
文章引用：樊纯祯, 王军珂, 戴红艳. 脂肪细胞因子在心血管疾病中的研究进展[J]. 临床医学进展, 2022, 12(10): 9288-9293. https://doi.org/10.12677/ACM.2022.12101343

参考文献

[1] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2021概要[J]. 中国循环杂志, 2022, 37(6): 553-578.
[2] Reamy, B.V., Williams, P.M. and Kuckel, D.P. (2018) Prevention of Cardiovascular Disease. Primary Care, 45, 25-44. [Google Scholar] [CrossRef] [PubMed]
[3] Watanabe, T., Watanabe-Kominato, K., Takahashi, Y., Kojima, M. and Watanabe, R. (2017) Adipose Tissue-Derived Omentin-1 Function and Regulation. Comprehensive Physiology, 7, 765-781. [Google Scholar] [CrossRef] [PubMed]
[4] Van de Voorde, J., Pauwels, B., Boydens, C. and Decaluwe, K. (2013) Adipocytokines in Relation to Cardiovascular Disease. Metabolism, 62, 1513-1521. [Google Scholar] [CrossRef] [PubMed]
[5] Kern, P.A., Lu, T., Rassouli, N. and Ranganathan, G. (2003) Adiponectin Expression from Human Adipose Tissue: Relation to Obesity, Insulin Resistance, and Tumor Necrosis Fac-tor-Alpha Expression. Diabetes, 52, 1779-1785. [Google Scholar] [CrossRef] [PubMed]
[6] Lee, B. and Shao, J. (2014) Adiponectin and Energy Homeostasis. Reviews in Endocrine and Metabolic Disorders, 15, 149-156. [Google Scholar] [CrossRef] [PubMed]
[7] Ohashi, K., Ouchi, N. and Matsuzawa, Y. (2012) An-ti-Inflammatory and Anti-Atherogenic Properties of Adiponectin. Biochimie, 94, 2137-2142. [Google Scholar] [CrossRef] [PubMed]
[8] Inoue, T., Kotooka, N., Morooka, T., Komoda, H., Uchida, T., Aso, Y., et al. (2007) High Molecular Weight Adiponectin as a Predictor of Long-Term Clinical Outcome in Patients with Coronary Artery Disease. American Journal of Cardiology, 100, 569-574. [Google Scholar] [CrossRef] [PubMed]
[9] Zhang, M., Chen, X., Zhu, Y., Yin, L., Quan, Z., Ou, Y., et al. (2022) Causal Associations of Circulating Adiponectin with Cardiometabolic Diseases and Osteoporotic Fracture. Scien-tific Reports, 12, Article No. 6689. [Google Scholar] [CrossRef] [PubMed]
[10] Di Chiara, T., Licata, A., Argano, C., Duro, G., Corrao, S. and Scaglione, R. (2014) Plasma Adiponectin: A Contributing Factor for Cardiac Changes in Visceral Obesity-Associated Hypertension. Blood Pressure, 23, 147-153. [Google Scholar] [CrossRef] [PubMed]
[11] Chen, Z., Peng, I.C., Sun, W., Su, M.I., Hsu, P.H., Fu, Y., et al. (2009) AMP-Activated Protein Kinase Functionally Phosphorylates Endothelial Nitric Oxide Synthase Ser633. Cir-culation Research, 104, 496-505. [Google Scholar] [CrossRef] 
[12] Kim, Y., Lim, J.H., Kim, E.N., Hong, Y.A., Park, H.J., Chung, S., et al. (2022) Adiponectin Receptor agonist Ameliorates Cardiac Lipotoxicity via Enhancing Ceramide Metab-olism in Type 2 Diabetic Mice. Cell Death & Disease, 13, Article No. 282. [Google Scholar] [CrossRef] [PubMed]
[13] Ouchi N KS, Arita, Y., Nishida, M., Matsuyama, A., Okamoto, Y., Ishigami, M., Kuriyama, H., et al. (2001) Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accu-mulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages. Circulation, 103, 1057-1063. [Google Scholar] [CrossRef] 
[14] Naryzhnaya, N.V., Koshelskaya, O.A., Kologrivova, I.V., Suslova, T.E., Kharitonova, O.A., Andreev, S.L., et al. (2022) Production of Reactive Oxygen Species by Epicardial Adipocytes Is Associated with an Increase in Postprandial Glycemia, Postprandial Insulin, and a Decrease in Serum Adiponectin in Patients with Severe Coronary Atherosclerosis. Biomedicines, 10, Article No. 2054. [Google Scholar] [CrossRef] [PubMed]
[15] George, J., Patal, S., Wexler, D., Sharabi, Y., Peleg, E., Kamari, Y., et al. (2006) Circulating Adiponectin Concentrations in Patients with Congestive Heart Failure. Heart, 92, 1420-1424. [Google Scholar] [CrossRef] [PubMed]
[16] Kojima, S., Funahashi, T., Otsuka, F., Maruyoshi, H., Yamashita, T., Kajiwara, I., et al. (2007) Future Adverse Cardiac Events Can Be Predicted by Persistently Low Plasma Adiponectin Concentrations in Men and Marked Reductions of Adiponectin in Women after Acute Myocardial Infarction. Athero-sclerosis, 194, 204-213. [Google Scholar] [CrossRef] [PubMed]
[17] Zhang Y PR, Maffei, M., Barone, M., Leopold, L. and Friedman, J.M. (1994) Positional Cloning of the Mouse Obese Gene and Its Human Homologue. Nature, 372, 425-32. [Google Scholar] [CrossRef] [PubMed]
[18] Friedman, J.M. (1998) Leptin, Leptin Receptors, and the Control of Body Weight. Nutrition Reviews, 56, S38-S46. [Google Scholar] [CrossRef] [PubMed]
[19] Liberale, L., Bonaventura, A., Vecchie, A., Casula, M., Dallegri, F., Montecucco, F., et al. (2017) The Role of Adipocytokines in Coronary Atherosclerosis. Current Athero-sclerosis Reports, 19, Article No. 21. [Google Scholar] [CrossRef] [PubMed]
[20] Vasamsetti, S.B., Natarajan, N., Sadaf, S., Florentin, J. and Dutta, P. (2022) Regulation of Cardiovascular Health and Disease by Visceral Adipose Tissue-Derived Metabolic Hormones. The Journal of Physiology. [Google Scholar] [CrossRef] 
[21] Huang, F., Xiong, X., Wang, H., You, S. and Zeng, H. (2010) Lep-tin-Induced Vascular Smooth Muscle Cell Proliferation via Regulating Cell Cycle, Activating ERK1/2 and NF-κB. Acta Biochim Biophys Sin (Shanghai), 42, 325-331. [Google Scholar] [CrossRef] [PubMed]
[22] Cirillo, P., Angri, V., De Rosa, S., Cali, G., Petrillo, G., Maresca, F., et al. (2010) Pro-Atherothrombotic Effects of Leptin in Human Coronary Endothelial Cells. Thrombosis and Haemostasis, 103, 1065-1075. [Google Scholar] [CrossRef] 
[23] Puurunen, V.P., Kiviniemi, A., Lepojarvi, S., Piira, O.P., Hedberg, P., Junttila, J., et al. (2017) Leptin Predicts Short- Term Major Adverse Cardiac Events in Patients with Coronary Artery Disease. Annals of Medicine, 49, 448-454. [Google Scholar] [CrossRef] [PubMed]
[24] Hasan-Ali, H., Abd El-Mottaleb, N.A., Hamed, H.B. and Abd-Elsayed, A. (2011) Serum Adiponectin and Leptin as Predictors of the Presence and Degree of Coronary Athero-sclerosis. Coronary Artery Disease, 22, 264-269. [Google Scholar] [CrossRef] 
[25] Faxen, U.L., Hage, C., Andreasson, A., Donal, E., Daubert, J.C., Linde, C., et al. (2017) HFpEF and HFrEF Exhibit Different Phenotypes as Assessed by Leptin and Adiponectin. International Journal of Cardiology, 228, 709-716. [Google Scholar] [CrossRef] [PubMed]
[26] Bidulescu, A., Liu, J., Chen, Z., Hickson, D.A., Musani, S.K., Samdarshi, T.E., et al. (2013) Associations of Adiponectin and Leptin with Incident Coronary Heart Disease and Is-chemic Stroke in African Americans: The Jackson Heart Study. Frontiers in Public Health, 1, Article No. 16. [Google Scholar] [CrossRef] [PubMed]
[27] Yang, H., Guo, W., Li, J., Cao, S., Zhang, J., Pan, J., et al. (2017) Leptin Concentration and Risk of Coronary Heart Disease and Stroke: A Systematic Review and Meta-Analysis. PLOS ONE, 12, e0166360. [Google Scholar] [CrossRef] [PubMed]
[28] Seven, E., Husemoen, L.L., Sehested, T.S., Ibsen, H., Wachtell, K., Linneberg, A., et al. (2015) Adipocytokines, C-Reactive Protein, and Cardiovascular Disease: A Population-Based Prospective Study. PLOS ONE, 10, Article ID: e0128987. [Google Scholar] [CrossRef] [PubMed]
[29] Romere, C., Duerrschmid, C., Bournat, J., Constable, P., Jain, M., Xia, F., et al. (2016) Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Cell, 165, 566-579. [Google Scholar] [CrossRef] [PubMed]
[30] Duerrschmid, C., He, Y., Wang, C., Li, C., Bournat, J.C., Romere, C., et al. (2017) Asprosin Is a Centrally Acting Orexigenic Hormone. Nature Medicine, 23, 1444-1453. [Google Scholar] [CrossRef] [PubMed]
[31] Moradi, N., Fouani, F.Z., Vatannejad, A., Bakhti Arani, A., Shahrzad, S. and Fadaei, R. (2021) Serum Levels of Asprosin in Patients Diagnosed with Coronary Artery Disease (CAD): A Case-Control Study. Lipids in Health and Disease, 20, Article No. 88. [Google Scholar] [CrossRef] [PubMed]
[32] Ovali, M.A. and Bozgeyik, I. (2022) Asprosin, a C-Terminal Cleavage Product of Fibrillin 1 Encoded by the FBN1 Gene, in Health and Disease. Molecular Syndromology, 13, 175-183. [Google Scholar] [CrossRef] [PubMed]
[33] Zhu, Q., Ni, X.Q., Lu, W.W., Zhang, J.S., Ren, J.L., Wu, D., et al. (2017) Intermedin Reduces Neointima Formation by Regulating Vascular Smooth Muscle Cell Phenotype via cAMP/PKA Pathway. Atherosclerosis, 266, 212-222. [Google Scholar] [CrossRef] [PubMed]
[34] Wang, R. and Hu, W. (2021) Asprosin Promotes Be-ta-Cell Apoptosis by Inhibiting the Autophagy of Beta-Cell via AMPK-mTOR Pathway. Journal of Cellular Physiology, 236, 215-221. [Google Scholar] [CrossRef] [PubMed]
[35] Lee, T., Yun, S., Jeong, J.H. and Jung, T.W. (2019) Aspros-in Impairs Insulin Secretion in Response to Glucose and viability through TLR4/JNK-mediated inflammation. Molecular and Cellular Endocrinology, 486, 96-104. [Google Scholar] [CrossRef] [PubMed]
[36] Zou, J., Xu, C., Zhao, Z.W., Yin, S.H. and Wang, G. (2022) Asprosin Inhibits Macrophage Lipid Accumulation and Reduces Atherosclerotic Burden by Up-Regulating ABCA1 and ABCG1 Expression via the p38/Elk-1 Pathway. Journal of Translational Medicine 20, Article No. 337. [Google Scholar] [CrossRef] [PubMed]
[37] Guven, C. and Kafadar, H. (2022) Evaluation of Plasma Asprosin Concentration in Patients with Coronary Artery Disease. Brazilian Journal of Cardiovascular Surgery, 37, 493-500. [Google Scholar] [CrossRef] [PubMed]
[38] 徐佰达, 叶挺, 王倩, 马涛, 刘洁, 宗刚军. 血浆白脂素水平与冠心病的关系[J]. 心脏杂志, 2019, 31(4): 428-431.
[39] Wang, H.H., Luo, W.Y., Lin, M., Li, X.J., Xiang, G.D. and Triganti, D.T. (2021) Plasma Asprosin, CCDC80 and ANGPTL4 Levels Are Associated with Meta-bolic and Cardiovascular Risk in Patients with Inflammatory Bowel Disease. Physiological Research, 70, 203-211. [Google Scholar] [CrossRef] [PubMed]
[40] Zhang, Z., Tan, Y., Zhu, L., Zhang, B., Feng, P., Gao, E., et al. (2019) Asprosin Improves the Survival of Mesenchymal Stromal Cells in Myocardial Infarction by Inhibiting Apoptosis via the Activated ERK1/2-SOD2 Pathway. Life Sciences, 231, Article ID: 116554. [Google Scholar] [CrossRef] [PubMed]
[41] Deng, X., Zhao, Z., Zhao, L., Wang, C., Li, Y., Cai, Z., et al. (2022) Association between Circulating Asprosin Levels and Carotid Atherosclerotic Plaque in Patients with Type 2 Diabetes. Clinical Biochemistry. [Google Scholar] [CrossRef] [PubMed]

为你推荐